Drugs / APL-5125
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06399757 | Jun 2024 → Apr 2027 expected | appendix adenocarcinoma, cholangiocarcinoma, endometrium adenocarcinoma, gastric adenocarcinoma +4 | Apollo Therapeutics Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-5125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06399757 ↗ |
| Route | Oral | “APL-5125 is an oral drug” NCT06399757 ↗ |